Recent reporting by King’s College London highlights a milestone in mental health research: the UK’s first publicly funded randomised controlled trial of psilocybin for depression has delivered very promising results.

Published in Nature Medicine, the PsiDeR trial recruited 60 people living with treatment-resistant depression – depression that had not responded to at least two prior treatments. Half received a single 25mg dose of psilocybin alongside structured psychological support; the other half received a placebo with the same support. By week three, 40 percent of the psilocybin group had reached remission, compared with just 3 percent on placebo – a difference that held at six weeks.

Two details stand out. The trial was funded by the UK’s National Institute for Health and Care Research and delivered within the NHS – a sign that rigorous, publicly accountable research into plant-based therapies is entering the mainstream. And much of the treatment took place safely in a calm community setting rather than a hospital, pointing toward models of care that meet people where they are. Lead investigator Professor James Rucker noted that the wider evidence base for psilocybin therapy “looks increasingly promising.”

At the Maccabeus Foundation, we follow research like this closely as part of our commitment to evidence-informed, dignified mental health care and to responsible legal frameworks for emerging therapies. Findings like these strengthen the case for hope: even long-standing depression can lift.

Read the original article on King’s College London to learn more.